Lilly pulls back from Foghorn's synthetic lethality work as biotech sheds 40% of staff
Eli Lilly is walking away from Foghorn Therapeutics' "synthetic lethality" drug development, and the small biotech is reducing its headcount by 40% as a result of the culled collaboration. The duo is dropping a Phase ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.